TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2142486

Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg per day
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Teicoplanin for proven or presumed Gram-positive infection
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Teicoplanin for skin and soft tissue infections
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Teicoplanin therapy
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Teicoplanin serum concentrations
Number of subjects: 202
Study: 282051

Group type: EXPERIMENTAL
Intervention: Indomethacin alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Indomethacin with diuretic or propranolol therapy
Number of subjects: 3
Study: 30418549

Group type: EXPERIMENTAL
Intervention: Cluster Randomized Trials (CRTs)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Individually Randomized Trials (IRTs)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pharmacological intervention
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Objective outcome
Number of subjects: 121
Study: 27027847

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 57
Study: 26011208

Group type: EXPERIMENTAL
Intervention: Modified Limberg flap (MLF)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Karydakis flap (KF)
Number of subjects: 91
Study: 23490226

Group type: EXPERIMENTAL
Intervention: MF/F 100/10 μg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MF/F 200/10 μg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MF/F 400/10 μg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MF-MDI 200 μg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MF 200 μg via DPI
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 21607966

Group type: EXPERIMENTAL
Intervention: Electrodiagnostic consultations performed by specialists (neurologists and physiatrists)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Electrodiagnostic consultations performed by non-specialists
Number of subjects: 100
Study: 19628108

Group type: EXPERIMENTAL
Intervention: Chia seed (CS) 25 g mixed in 0.25 L water twice daily for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (P) 25 g mixed in 0.25 L water twice daily for 12 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chia seed (CS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 90
Study: 16436796

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14687300

Group type: EXPERIMENTAL
Intervention: Neonatal Nurse Practitioner (NNP) model of practice
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pre-intervention survey
Number of subjects: 2

Group type: COMPARATOR
Intervention: Post-intervention survey
Number of subjects: 2
Study: 11349172

Group type: EXPERIMENTAL
Intervention: Forceps-assisted delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vacuum-assisted delivery
Number of subjects: 0
Study: 9261749

Group type: EXPERIMENTAL
Intervention: Individual psychotherapy and psychopharmacological treatment (study group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine oncological care (control group)
Number of subjects: 100
Study: 7952799

Group type: EXPERIMENTAL
Intervention: 100 mg furosemide preadsorbed onto 160 mg charcoal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg furosemide preadsorbed onto 200 mg charcoal
Number of subjects: 8

Group type: COMPARATOR
Intervention: 40 mg furosemide only (reference)
Number of subjects: 8
Study: 2977280

Group type: EXPERIMENTAL
Intervention: Fenfluramine treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Baseline autistic group
Number of subjects: 9
Study: 30291883

Group type: EXPERIMENTAL
Intervention: Hypothermia (target 33.0 °C)
Number of subjects: 624
Study: 26940688

Group type: EXPERIMENTAL
Intervention: AC->T (doxorubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 3298

Group type: COMPARATOR
Intervention: TAC (docetaxel, doxorubicin, and cyclophosphamide)
Number of subjects: 3298

Group type: EXPERIMENTAL
Intervention: AC->T
Number of subjects: 3298

Group type: COMPARATOR
Intervention: TAC
Number of subjects: 3298
Study: 24144196

Group type: EXPERIMENTAL
Intervention: levomilnacipran ER 40 mg/day
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: levomilnacipran ER 80 mg/day
Number of subjects: 557

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 557
Study: 22698294

Group type: EXPERIMENTAL
Intervention: Manual reduction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermaxillary fixation (IMF)
Number of subjects: 50
Study: 21155174

Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV9)
Number of subjects: 39836

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39836

Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV9) in HIV-infected children
Number of subjects: 39836

Group type: COMPARATOR
Intervention: Placebo in HIV-infected children
Number of subjects: 39836

Group type: EXPERIMENTAL
Intervention: Possible/probable PTB
Number of subjects: 39836
Study: 17275026

Group type: EXPERIMENTAL
Intervention: Multimedia educational aids (video- or computer-based)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Routine procedures
Number of subjects: 37
Study: 16643909

Group type: EXPERIMENTAL
Intervention: Doppler assessment of blood flow to the follicle and the endometrium; serum concentrations of biochemical markers such as anti‐Müllerian hormone, inhibin B, FSH, LH, and P
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Women with recurrent miscarriage
Number of subjects: 44
Study: 12829991

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 10723108

Group type: EXPERIMENTAL
Intervention: Family risk score (FRS)
Number of subjects: 13938
Study: 8857016

Group type: EXPERIMENTAL
Intervention: Elevated cardiac troponin T levels (> 0.1 ng/mL)
Number of subjects: 855

Group type: COMPARATOR
Intervention: Lower cardiac troponin T levels (≤ 0.1 ng/mL)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Electrocardiographic category (ST-segment elevation, ST-segment depression, T-wave inversion)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: CK-MB levels
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Combined model of troponin T levels, electrocardiographic categories, and CK-MB levels
Number of subjects: 855
Study: 1536246

Group type: EXPERIMENTAL
Intervention: Betamethasone (two doses of 12 mg, 24 hours apart)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 77
Study: 6401442

Group type: EXPERIMENTAL
Intervention: Oral nifedipine 10‐20 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous clonidine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31378506

Group type: EXPERIMENTAL
Intervention: Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 109
Study: 31621982

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment
Number of subjects: 384
Study: 30439309

Group type: EXPERIMENTAL
Intervention: cf‐DNA in sepsis group (μg/L): 1,438.0 (1,154.0, 1,576.0)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: cf‐DNA in severe sepsis group (μg/L): 2,595.0 (2,162.0, 5,198.0)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PCT in sepsis group (μg/L): 5.80 (3.28, 8.85)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PCT in severe sepsis group (μg/L): 17.53 (8.40, 29.61)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: APACHE II score in sepsis group: 13.04±3.03
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: APACHE II score in severe sepsis group: 23.29±8.02
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: cf‐DNA, PCT, APACHE II combined prediction
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: cf‐DNA alone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PCT alone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: APACHE II alone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: cf‐DNA + PCT
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: cf‐DNA + APACHE II
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PCT + APACHE II
Number of subjects: 105
Study: 27050801

Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (F/S) in Gly/Gly subjects
Number of subjects: 67

Group type: COMPARATOR
Intervention: Fluticasone alone (F) in Gly/Gly subjects
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (F/S) in Arg/Arg subjects
Number of subjects: 67

Group type: COMPARATOR
Intervention: Fluticasone alone (F) in Arg/Arg subjects
Number of subjects: 67
Study: 24379169

Group type: EXPERIMENTAL
Intervention: CPAP and a 6-month behavioral medicine intervention targeting physical activity (PA) and eating behavior (EB)
Number of subjects: 73

Group type: COMPARATOR
Intervention: CPAP and advice on the association between weight and OSAS
Number of subjects: 73
Study: 21987045

Group type: EXPERIMENTAL
Intervention: Percutaneous needle fasciotomy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Limited fasciectomy
Number of subjects: 111
Study: 19130641

Group type: EXPERIMENTAL
Intervention: Hypertrophy protocol (4 sets of 10 repetitions at 75% 1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Strength protocol (11 sets of 3 repetitions at 90% 1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Power protocol (8 sets of 6 repetitions of jump squats at 0% 1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Total work (TW) calculated for all protocols
Number of subjects: 10
Study: 18422060

Group type: EXPERIMENTAL
Intervention: Mean corpuscular hemoglobin concentration (MCHC) in patients with hereditary spherocytosis (35.67±1.33 g/dl)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) in patients with hereditary spherocytosis (20.60±4.5%)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of MCHC and RDW
Number of subjects: 94
Study: 15209811

Group type: EXPERIMENTAL
Intervention: Prednisone 20 mg oral daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 11576365

Group type: EXPERIMENTAL
Intervention: Index of Coexistent Disease (ICED)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Model R2
Number of subjects: 1000
Study: 9704373

Group type: EXPERIMENTAL
Intervention: 50 units of botulinum toxin type A
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 100 units of botulinum toxin type A
Number of subjects: 33

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 100 units of botulinum toxin type A (second injection)
Number of subjects: 33
Study: 7988607

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 127
Study: 2563797

Group type: EXPERIMENTAL
Intervention: Individual hypnotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group hypnotherapy (up to 8 patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (individual and group)
Number of subjects: 33
Study: 29996813

Group type: EXPERIMENTAL
Intervention: App-based intervention including unintentional injury prevention
Number of subjects: 2626

Group type: COMPARATOR
Intervention: Routine education plus app-based parenting education excluding unintentional injury prevention (Control)
Number of subjects: 2626
Study: 28427442

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (intervention group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sham acupuncture (control group)
Number of subjects: 136
Study: 26238547

Group type: COMPARATOR
Intervention: Routine Hemoperfusion (HP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intensive Hemoperfusion (HP)
Number of subjects: 14
Study: 24154906

Group type: EXPERIMENTAL
Intervention: Transhepatic biopsies
Number of subjects: 10

Group type: COMPARATOR
Intervention: Extrahepatic biopsies
Number of subjects: 10
Study: 20070280

Group type: EXPERIMENTAL
Intervention: 30 mg EPs‐7630
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 60 mg EPs‐7630
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 90 mg EPs‐7630
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 18327889

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 44
Study: 16571394

Group type: EXPERIMENTAL
Intervention: Neuromuscular electric stimulation (NMES) of the tibialis anterior muscle for 10 minutes, combined with conventional stroke rehabilitation program (5 days a week for 4 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional stroke rehabilitation program (5 days a week for 4 weeks)
Number of subjects: 25
Study: 12589167

Group type: EXPERIMENTAL
Intervention: Quadruple immunosuppressive therapy (interleukin (IL)‐2 receptor antibody, tacrolimus, mycophenolate mofetil, and prednisone)
Number of subjects: 1
Study: 10645510

Group type: EXPERIMENTAL
Intervention: Performance feedback only
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Patient education materials only
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Both feedback and education materials
Number of subjects: 216

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 216
Study: 8986564

Group type: COMPARATOR
Intervention: Indwelling Foley catheter (group 1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Intermittent catheterization (group 2)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Indwelling Foley catheter
Number of subjects: 119
Study: 1280802

Group type: EXPERIMENTAL
Intervention: 200 mg ibuprofen plus 30 mg codeine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 200 mg ibuprofen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3894278

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study: 31399392

Group type: EXPERIMENTAL
Intervention: Suicide attempters (n=22)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ideating nonattempters (n=46)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Behavioral performance indices
Number of subjects: 68
Study: 29884164

Group type: EXPERIMENTAL
Intervention: NIATx implementation strategies, including coaching and learning sessions over a 12‐month intervention period
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study: 26303195

Group type: EXPERIMENTAL
Intervention: Increasing fat intake from <25 to >35 %
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Increasing carbohydrates intake from <45 to >60 %
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Fiber intake >15 g/1000 kcal
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Consumption of added sugars of >10 % of the energy intake
Number of subjects: 1785
Study: 24746599

Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right transradial access
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left transradial access
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 0
Study: 22104345

Group type: EXPERIMENTAL
Intervention: Saphenofemoral ligation with stripping and multiple phlebectomies (group S)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (group F)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (standard surgery)
Number of subjects: 73
Study: 20885315

Group type: EXPERIMENTAL
Intervention: Prompt coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial strategy of PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CABG in patients with more extensive CAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 0
Study: 18507656

Group type: EXPERIMENTAL
Intervention: Atropine (5 mg intravenously)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atropine (administered at the time of the nadir)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fingolimod (5 mg orally)
Number of subjects: 12
Study: 16132406

Group type: EXPERIMENTAL
Intervention: Octreotide 0.1 mg subcutaneously 3 times/day for a total of 7 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: No octreotide
Number of subjects: 105
Study: 11950022

Group type: EXPERIMENTAL
Intervention: Telephone administration of WOMAC LK3.0 Index
Number of subjects: 50

Group type: COMPARATOR
Intervention: Onsite completion of WOMAC LK3.0 Index
Number of subjects: 50
Study: 10225505

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy (Trauma Treatment Protocol; TTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 0
Study: 7549839

Group type: EXPERIMENTAL
Intervention: VAD (vincristine, doxorubicin, dexamethasone)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MOD (mitozantrone, vincristine, dexamethasone)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (comparison between VAD and MOD)
Number of subjects: 67
Study: 2084755

Group type: EXPERIMENTAL
Intervention: Form 1 of the Selective Reminding Test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Form 2 of the Selective Reminding Test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Form 3 of the Selective Reminding Test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Form 4 of the Selective Reminding Test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Form 5 of the Selective Reminding Test
Number of subjects: 90
Study: 310917

Group type: EXPERIMENTAL
Intervention: Prophylactic digitalization with digoxin (1 or 1.5 mg before operation, 0.25 mg daily postoperatively)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Digoxin dosage comparison (1 mg vs. 1.5 mg)
Number of subjects: 140
Study: 31358243

Group type: EXPERIMENTAL
Intervention: Abdominal massage (15-min video-guided training, performed twice a day for 4 weeks)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard approach of the clinic (control group)
Number of subjects: 204
Study: 29354953

Group type: EXPERIMENTAL
Intervention: Wrist‐ankle needle therapy combined with patient controlled intravenous analgesia (PCIA)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Simple PCIA
Number of subjects: 98
Study: 26164267

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (five different compounds)
Number of subjects: 2666
Study: 23410138

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 265
Study: 21396901

Group type: EXPERIMENTAL
Intervention: 9 valent pneumococcal conjugate vaccines (3 doses in infancy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster dose at 9 months or early in the second year of life (suggested for evaluation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving the vaccine)
Number of subjects: 0
Study: 18312558

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet and exercise training
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study: 17634547

Group type: EXPERIMENTAL
Intervention: 2.5 mg/d tibolone for 14 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 102
Study: 12605619

Group type: EXPERIMENTAL
Intervention: Salvia officinalis extract (60 drops/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10863911

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen (50% mix)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 87
Study: 9184268

Group type: EXPERIMENTAL
Intervention: Antidepressant drugs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: NSAID
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Muscle relaxant drugs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 35
Study: 1404819

Group type: EXPERIMENTAL
Intervention: 20 mg/d of tacrine
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: 40 mg/d of tacrine
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: 80 mg/d of tacrine
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 3932677

Group type: COMPARATOR
Intervention: 5 percent dextrose (Group I)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (Group II)
Number of subjects: 12
Study: 30267257

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pazopanib
Number of subjects: 0
Study: 26497535

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy (MBT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 64
Study: 24408114

Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration (HDF)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 342
Study: 22387079

Group type: EXPERIMENTAL
Intervention: Pump flow rate at 80% of theoretic value
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pump flow rate at 100% of theoretic value
Number of subjects: 30
Study: 20140462

Group type: EXPERIMENTAL
Intervention: Landiolol (0.125 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 14
Study: 18621625

Group type: EXPERIMENTAL
Intervention: Topotecan (2 mg per day or 2.5 mg per day fixed dose for 5 of 7 days for 2 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 21 days)
Number of subjects: 80